Theranostics of triple negative breast cancer: a review
نویسندگان
چکیده
INTRODUCTION: Triple negative cancer is one of the most aggressive subtypes breast cancer. Currently, no effective treatment methods have been proposed that would significantly affect long-term results treatment. OBJECTIVE: To summarize possibilities theranostics and nanteranostics in visualization elimination malignant cells immunosuppressive microenvironment thriple MATERIALS AND METHODS: A search was conducted for scientific publications PubMed information analytical system 2015–2022 by keywords: «triple cancer» («triple cancer»), «signaling pathways» («signaling pathways»), «tumor microenvironment» («tumor microenvironment»), «cancer stem cells» («stem tumor cells»), «theranostics», «nanomaterials» («nanomaterials»), «nanotheranostics» («nanoteranostics»). After excluding articles devoted to technical aspects molecular biological research, 57 related thrice-negative were analyzed. RESULTS: Targets triple are associated with components microenvironment. The article presents data on composition interaction between various cellular subpopulations microenvironment, as well role its formation. State art classifications defects presented. stem, differentiated described. authors present their own nature distribution which should be taken into account when choosing effect tumor. applications radiopharmaceuticals nanoparticle-based preparations developed date CONCLUSION: characterized presence a large number biomarkers can targets diagnostic therapeutic drugs. It advisable use artificial intelligence technologies selection. nanoparticles makes it possible reduce toxicity ensure implementation several simultaneously.
منابع مشابه
A review of triple-negative breast cancer.
BACKGROUND An estimated 1 million cases of breast cancer are diagnosed annually worldwide. Of these, more than 170,000 are described as triple-negative. Triple-negative breast cancer (TNBC) is defined by the lack of protein expression of estrogen receptor (ER) and progesterone receptor (PR) and the absence of HER2 protein overexpression. TNBC is a subtype of breast cancer that overlaps with the...
متن کاملClinicopathological Features of Non-metastatic Triple Negative Breast Cancer
Background: Triple negative breast cancer (TNBC) is reported to be associated with a high risk of recurrence, poor overall survival (OS), and disease-free survival (DFS) rates. This study evaluated the clincopathological features and survival of non-metastatic TNBC women in the capital of Iran compared with other areas of the world. Methods: In a retrospective study, 119 women with TNBC based ...
متن کاملFuture of Triple Negative Breast Cancer: Can Immunotherapy Treat This Deadly Subtype of Breast Cancer?
Triple negative breast cancer (TNBC): challenges and solutions via the immune cells TNBC is one of the most complicated types of breast cancer to treat. It is generally diagnosed based on the absence of three receptors: estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) and is thus defined as a triple negative. TNBC is often more aggressive with lower survival rates...
متن کاملTriple-Negative Breast Cancer
Triple-negative breast cancer, so called because it lacks expression of the estrogen receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast cancer. This review focuses on its origin, molecular and clinical characteristics, and treatment.
متن کاملTriple-Negative Breast Cancer
From the Program in Cancer Genetics, the Research Institute of the McGill University Health Centre, and the Lady Davis Institute of the Jewish General Hospital (W.D.F.); McGill University, Montreal; and the Breast Unit, Royal Marsden Hospital and Institute of Cancer Research (I.E.S.), and the Breakthrough Breast Cancer Research Centre, Institute of Cancer Research (J.S.R.-F.) — both in London. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Lu?evaâ diagnostika i terapiâ
سال: 2023
ISSN: ['2079-5343', '2079-5351']
DOI: https://doi.org/10.22328/2079-5343-2023-14-2-15-30